## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

# **Listing of Claims:**

1. (Currently amended) A sterile patch comprising a breathable backing coated with a cross-linked polyvinylpyrrolidone-based hydrogel, wherein the breathable backing displays a moisture vapor transmission rate (MVTR) value within the range of from about 500 to about 5000 g/m²/d and comprises a copolymer film wherein the copolymer is a copolymer of a polyester and a polyether, wherein the hydrogel comprises from about 5% to about 35% by weight polyvinylpyrrolidone, and wherein the hydrogel comprises from about 0.5% to about 20% by weight of a local anesthetic or a pharmaceutically acceptable salt thereof, and wherein the hydrogel further comprises a preservative.

#### 2-4. Canceled.

- 5. (**Previously presented**) The patch of claim 1, wherein the local anesthetic comprises a sodium-channel blocker or a pharmaceutically acceptable salt thereof.
- 6. (**Previously presented**) The patch of claim 5, wherein the sodium-channel blocker is lidocaine.

## 7 – 11. **Canceled**.

12. (Currently amended) A package containing a sterile patch, the patch comprising a breathable backing coated with a cross-linked polyvinylpyrrolidone-based hydrogel, wherein the breathable backing displays a moisture vapor transmission rate (MVTR) value within the range of from about 500 to about 5000 g/m²/d and comprises a copolymer film wherein the copolymer is a copolymer of a polyester and a polyether, wherein the hydrogel comprises from about 5% to about 35% by weight polyvinylpyrrolidone, and wherein the hydrogel comprises about 10% by weight of a local anesthetic or a pharmaceutically acceptable salt thereof, and wherein the hydrogel further comprises a preservative.

#### 13-14. Canceled.

- 15. (**Previously presented**) The package of claim 12, wherein the local anesthetic comprises a sodium-channel blocker or a pharmaceutically acceptable salt thereof.
- 16. (**Previously presented**) The package of claim 15, wherein the sodium-channel blocker is lidocaine.

### 17 – 21. Canceled.

22. (Currently amended) A method of inducing local anesthesia in a mammal comprising topically applying a sterile patch to the mammal, the patch comprising a breathable backing coated with a cross-linked polyvinylpyrrolidone-based hydrogel, wherein the breathable backing displays a moisture vapor transmission rate (MVTR) value within the range of from about 500 to about 5000 g/m²/d and comprises a copolymer film wherein the copolymer is a copolymer of a polyester and a polyether, wherein the hydrogel comprises from about 5% to about 35% by weight polyvinylpyrrolidone, and wherein the hydrogel comprises about 10% by weight of a local anesthetic or a pharmaceutically acceptable salt thereof, and wherein the hydrogel further comprises a preservative.

#### 23-25. **Canceled**.

- 26. (Previously presented) The method of claim 22, wherein the local anesthetic comprises a sodium-channel blocker or a pharmaceutically acceptable salt thereof.
- 27. (**Previously presented**) The method of claim 26, wherein the sodium-channel blocker is lidocaine.

## 28 – 54. **Canceled**.

- 55. (**Previously presented**) The patch of claim 1, wherein the hydrogel comprises from about 10% to about 30%, by weight, of polyvinylpyrrolidone.
- 56. (**Previously presented**). The patch of claim 1, wherein the hydrogel comprises from about 2% to about 10%, by weight, of local anesthetic.

## 57-58. Canceled.

- 59. (**Previously presented**) The method of claim 22, wherein the patch is applied to non-intact skin on the mammal.
- 60. (**Previously presented**) The method of claim 59, wherein the patch is applied to a burn or wound of the skin.
- 61. (**Previously presented**) The method of claim 60, wherein the patch is applied to a surgically closed wound of the skin.
- 62. (Currently amended) The patch of claim 4 1, wherein the preservative is a blend of paraben esters in phenoxyethanol.
- 63. (Currently amended) The package of claim 14 12, wherein the preservative is a blend of paraben esters in phenoxyethanol.
- 64. (Currently amended) The method of claim 25 22, wherein the preservative is a blend of paraben esters in phenoxyethanol.
- 65. (Currently amended) A sterile patch comprising a breathable backing coated with a cross-linked polyvinylpyrrolidone-based hydrogel, wherein the breathable backing displays a moisture vapor transmission rate (MVTR) value within the range of from about 500 to about 5000 g/m²/d and comprises a copolymer film wherein the copolymer is a copolymer of a polyester and a polyether, wherein the hydrogel comprises from about 5% to about 35% by weight polyvinylpyrrolidone, and wherein the hydrogel comprises about 10% to about 20% by weight of a local anesthetic or a pharmaceutically acceptable salt thereof, and wherein the hydrogel further comprises a preservative.

## 66-67. Canceled.

- 68. (**Previously presented**) The patch of claim 65, wherein the local anesthetic comprises a sodium-channel blocker or a pharmaceutically acceptable salt thereof.
- 69. (**Previously presented**) The patch of claim 68, wherein the sodium-channel blocker is lidocaine.